Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2606)	9/25/2009 1:36:26 PM
From: Jibacoa	Respond to of 3722

ISRG is going over the resistance at the $250 level, without closing its July 23 UG and in spite of its poor report on the 1stQ, but with the help of better report on the 2ndQ. <g> The stock is up 5.05% with volume > its ADV. bigcharts.marketwatch.com ISRG has NSLTD, has +CF around $5.85 and the EE for 2009 and 2010 are $5.35 and $6.60 vs. the $5.12 in 2008 The short ratio had increased about 8% and was around 6x its ADV The ACTAY is $203, but it seems that if the general market improves, and with some good news, the stock could get to the $270 level.<g> bigcharts.marketwatch.com Bernard

To: Jibacoa who wrote (2606)	6/8/2010 1:01:31 PM
From: Jibacoa	1 Recommendation Read Replies (1) \| Respond to of 3722

DRRX is still up about 8.68% with volume now close to its ADV. bigcharts.marketwatch.com Yesterday it had a C.,C.,which was broadcasted live over the internet at 5:00pm to comment on the license agreement it had entered with HSP to develop and market POSIDUR in the U.S. and Canada. POSIDUR is DRRX's post-operative pain relief depot currently in PIII in the U.S. It is licensed to Nycomed for commercialization in Europe and other specified countries, and DRRX retains rights in Japan and all other countries. Under terms of the agreement, HSP will make an upfront payment of $27.5M, with the potential for up to an additional $185M in performance milestone payments based on the successful development, approval and commercialization of POSIDUR in the U.S. and Canada. <g> For the U.S. and Canada, the two companies will jointly direct and equally fund the remaining development costs for POSIDUR, while HSP will have exclusive commercialization rights upon regulatory approval, but will pay some royalties to DRRX. The ACTAY is $4.25 DRRX has no significant LTD, but has been burning its cash at a good clip.<g> The stock has a good amount of resistance at the $3 level and it isn;t completely off from its longer term DT. But with some good news and if it can go over $3 it seems should.t have much problem in getting to the $4 level. bigcharts.marketwatch.com Bernard